About Cellipont
Cellipont is a Healthcare company based in Poway (United States) founded in 2002, and was acquired by Great Point Partners in January 2022. Cell therapy development services are provided by CDMO Cellipont. Cellipont offers products and services including Clinical Manufacturing, Process Development, Analytical Development, and Allogeneic CAR-T Services. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Cell and Gene Therapy. Its competitors include Orgenesis and Cognate Bioservices.
Company details
Cellipont was established in 2002 and is based in Poway, United States. As a contract development and manufacturing organization, focus is placed on cell therapy development services within the biotechnology sector. Operations involve supporting clients through process development, manufacturing, and regulatory guidance for cellular therapies. Services are tailored to advance therapeutic products from early stages to clinical applications, with activities centered in the U.S. market.
- Headquarters Poway, United States
- Stage Acquired
- SectorsHealthcare
- Website cellipont.com
- Social LinkedIn X Instagram
- Acquired by Great Point Partners (Jan 2022)
- InvestorsOrbimed
& 1 more
- Acquired byGreat Point Partners
(Jan 2022)
Products & Services of Cellipont
Cellipont offers a comprehensive portfolio of products and services, including Clinical Manufacturing, Process Development, Analytical Development, and Allogeneic CAR-T Services.
Provides cGMP manufacturing for cell therapies and products
Develops processes for cell therapy production and optimization
Offers testing and analysis for cell therapy development
Specializes in manufacturing and development of CAR-T therapies
Funding Insights of Cellipont
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Cellipont with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | Debt – Conventional | – | – |
2 investors in total: 2 institutional.
Investors in Cellipont
Cellipont has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Orbimed and Great Point Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States |
Investor details for Cellipont
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellipont
1 people are tracked at Cellipont (1 in team).
| Name | Role | Group |
|---|---|---|
Deborah Wild | Board Member | Team |
Complete people profiles for Cellipont
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellipont
3 dated milestones of Cellipont across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Cellipont is founded.
- Exit Acquired by Great Point Partners.
- Funding First funding round.
Competitors of Cellipont
Cellipont has 2 listed competitors in our database. They include Orgenesis and Cognate Bioservices.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| orgenesis.com | 2008 | Germantown, United States | 167 | Cell and gene therapies for multiple disorders are developed. | ||
| cognatebioservices.com | 2002 | Hanover, United States | 302 | Development and manufacturing services for cell-based therapies are provided. |
Detailed competitors of Cellipont
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellipont
The website of Cellipont (cellipont.com) receives about 6.8K visits a month.
- Monthly visits6.8K
▲ 16.6% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Cellipont (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellipont
Complete news archive for Cellipont
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellipont
Cellipont was founded in 2002 and raised its 1st funding round 21 years after it was founded.
Cellipont is headquartered in Poway, United States. It is registered at Poway, California, United States.
Cellipont was established in 2002 and is based in Poway, United States. As a contract development and manufacturing organization, focus is placed on cell therapy development services within the biotechnology sector. Operations involve supporting clients through process development, manufacturing, and regulatory guidance for cellular therapies. Services are tailored to advance therapeutic products from early stages to clinical applications, with activities centered in the U.S. market.
Cellipont's top competitors include Orgenesis and Cognate Bioservices.
Cellipont offers Clinical Manufacturing, Process Development, Analytical Development, and Allogeneic CAR-T Services.
Cellipont has 2 investors. Key investors include Orbimed, and Great Point Partners.
Yes. Cellipont was acquired by Great Point Partners in January 2022.